Alexander Mansour, MBA
Advertisement
Articles by Alexander Mansour, MBA
The Centers for Medicare and Medicaid Services finalized a ruling that slashes reimbursement rates on drugs that qualify under the 340B program.
Advertisement
Latest Updated Articles
- Opinion: CMS 340B Reimbursement Cuts Cause Big Pharma Profits While Underserved Patients Lose
Published: January 4th 2018 | Updated:
Opinion: CMS 340B Reimbursement Cuts Cause Big Pharma Profits While Underserved Patients LosePublished: January 3rd 2018 | Updated:
Advertisement
Advertisement
Trending on Pharmacy Times
1
Guiding Patients With Sickle Cell Disease Through the Transformative Era of Gene Therapy
2
New Data Highlights Pharmacists’ Expanding Roles in Hematologic Malignancies
3
Bridging Response Emerges as Key Predictor of Cilta-Cel Outcomes in CARTITUDE-4
4
Deeper MRD Responses Strengthen Shared Decision-Making as Daratumumab Use Expands Across Treatment Phases
5
